PSA

Men must be entitled to PCa screening, treatment choiceThe following letter was sent to Urology Times in response to a previously published letter to the editor, "Dear USPSTF: Don't discount value of PSA in men 70+."
Dear USPSTF: Don’t discount value of PSA in men 70+“We strongly believe that PSA-based prostate cancer screening should be made available, especially to men 70 years and older to decrease the morbidity and mortality of prostate cancer,” write Navin Shah, MD, and Vladimir Ioffe, MD.
Genetic predictors could improve PSA accuracyA recent study has found that genetic predictors of normal PSA levels in healthy men could be used to improve the accuracy of PSA-based prostate cancer screening.
Studies reveal drop in PCa treatment, rise in metastatic diseaseFindings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.
USPSTF reform: PSA at forefront of Capitol Hill hearingOrganized urology makes its case for USPSTF reform during a recent hearing of the House Energy and Commerce Health Subcommittee.
Is 1.5 the new magic number for PSA screening?A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
There’s something about PSA: Ben Stiller fights the good fightUrologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.
Outcomes Analysis: Decline observed in PSA-based screening for PCaStudies about ProPublica's Surgeon Scorecard, urology participation in accountable care organizations, and Twitter were among the take-home messages in outcomes analysis at the 2016 AUA annual meeting. The take-homes were presented by Christopher Saigal, MD, MPH, of the University of California, Los Angeles.
Prostate Ca: PSA drop, active surveillance are key themesFusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting.
CMS halts PSA quality measure—for nowAs a result of strong opposition from organized medicine, including the AUA and patients, the Centers for Medicare & Medicaid Services has put on hold its development of a draft plan to penalize physicians for ordering “non-recommended” PSA tests to screen for prostate cancer.